Shionogi Pharma presents data on pivotal PSD502 for premature ejaculation primary in 2010 AUA Shionogi Pharma, Inc., based in a group of companies and the United States of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, metered dose spray currently being developed for the treatment of primary premature ejaculation (PE). These data were presented in 2010 by the American Association Urology (AUA) Annual Meeting in San Francisco.
The Medical Mystery Chronicles